Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients

Aim of the work: To assess urinary soluble CD163 (sCD136) in systemic lupus erythematosus (SLE) patients compared to healthy controls. In addition to determine its association with different SLE clinical features, laboratory investigations and pathological indices focusing on those suggest renal dis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nada M. Gamal, Eman R. Badawy, Esraa A Talaat, Hamdy M. Ibrahim, Mona H. Abd Elsamea
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Lupus nephritis Urinary soluble CD163 M2 macrophages Renal SLEDAI Urinary biomarkers Renal biopsy Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/1d3562f5393f4a25b3eca27a016c9314
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d3562f5393f4a25b3eca27a016c9314
record_format	dspace
spelling	oai:doaj.org-article:1d3562f5393f4a25b3eca27a016c93142021-11-12T04:26:59ZClinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients1110-116410.1016/j.ejr.2021.10.003https://doaj.org/article/1d3562f5393f4a25b3eca27a016c93142022-04-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1110116421000909https://doaj.org/toc/1110-1164Aim of the work: To assess urinary soluble CD163 (sCD136) in systemic lupus erythematosus (SLE) patients compared to healthy controls. In addition to determine its association with different SLE clinical features, laboratory investigations and pathological indices focusing on those suggest renal disease activity. Patients and methods: The study included 58 SLE patients and 30 controls. SLE disease activity index (SLEDAI) was assessed and patients subdivided into active lupus nephritis (ALN) (renal SLEDAI ≥ 4) and no-renal activity (NRA) SLE patients (renal SLEDAI = 0). Urinary sCD163 was measured by Enzyme-Linked Immunosorbent Assay (ELISA). Urine values were normalized to urinary creatinine excretion. Renal biopsies were performed in 21 ALN patients. Results: They were 54 females and 4 males with a mean age 31.8 ± 9.1 years and disease duration 6.2 ± 4.8 years. They were 31 with ALN and 27 NRA SLE patients. Urinary sCD163 level was significantly higher in SLE patients (1.85 ± 0.3) than controls (0.5 ± 0.36, p < 0.001). In ALN, it was significantly higher (2.91 ± 2.52) compared to NRA SLE patients (0.64 ± 0.38) and controls (p < 0.001 in both). The optimum cut-off value above which normalized urinary sCD136 can predict renal activity was > 0.82 with sensitivity of 90.3%, specificity of 88.89%, p < 0.001. Urinary sCD163 significantly correlated with renal (r = 0.75, p < 0.001) but not with extra-renal SLEDAI. It correlated with activity index of renal biopsy (r = 0.46, p = 0.038). Conclusion: Urinary sCD163 is a potential biomarker for LN activity. Its level is associated with clinical features, laboratory investigations and pathological indices that indicate renal disease activity.Nada M. GamalEman R. BadawyEsraa A TalaatHamdy M. IbrahimMona H. Abd ElsameaElsevierarticleLupus nephritisUrinary soluble CD163M2 macrophagesRenal SLEDAIUrinary biomarkersRenal biopsyImmunologic diseases. AllergyRC581-607ENEgyptian Rheumatologist, Vol 44, Iss 2, Pp 151-157 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lupus nephritis Urinary soluble CD163 M2 macrophages Renal SLEDAI Urinary biomarkers Renal biopsy Immunologic diseases. Allergy RC581-607
spellingShingle	Lupus nephritis Urinary soluble CD163 M2 macrophages Renal SLEDAI Urinary biomarkers Renal biopsy Immunologic diseases. Allergy RC581-607 Nada M. Gamal Eman R. Badawy Esraa A Talaat Hamdy M. Ibrahim Mona H. Abd Elsamea Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
description	Aim of the work: To assess urinary soluble CD163 (sCD136) in systemic lupus erythematosus (SLE) patients compared to healthy controls. In addition to determine its association with different SLE clinical features, laboratory investigations and pathological indices focusing on those suggest renal disease activity. Patients and methods: The study included 58 SLE patients and 30 controls. SLE disease activity index (SLEDAI) was assessed and patients subdivided into active lupus nephritis (ALN) (renal SLEDAI ≥ 4) and no-renal activity (NRA) SLE patients (renal SLEDAI = 0). Urinary sCD163 was measured by Enzyme-Linked Immunosorbent Assay (ELISA). Urine values were normalized to urinary creatinine excretion. Renal biopsies were performed in 21 ALN patients. Results: They were 54 females and 4 males with a mean age 31.8 ± 9.1 years and disease duration 6.2 ± 4.8 years. They were 31 with ALN and 27 NRA SLE patients. Urinary sCD163 level was significantly higher in SLE patients (1.85 ± 0.3) than controls (0.5 ± 0.36, p < 0.001). In ALN, it was significantly higher (2.91 ± 2.52) compared to NRA SLE patients (0.64 ± 0.38) and controls (p < 0.001 in both). The optimum cut-off value above which normalized urinary sCD136 can predict renal activity was > 0.82 with sensitivity of 90.3%, specificity of 88.89%, p < 0.001. Urinary sCD163 significantly correlated with renal (r = 0.75, p < 0.001) but not with extra-renal SLEDAI. It correlated with activity index of renal biopsy (r = 0.46, p = 0.038). Conclusion: Urinary sCD163 is a potential biomarker for LN activity. Its level is associated with clinical features, laboratory investigations and pathological indices that indicate renal disease activity.
format	article
author	Nada M. Gamal Eman R. Badawy Esraa A Talaat Hamdy M. Ibrahim Mona H. Abd Elsamea
author_facet	Nada M. Gamal Eman R. Badawy Esraa A Talaat Hamdy M. Ibrahim Mona H. Abd Elsamea
author_sort	Nada M. Gamal
title	Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
title_short	Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
title_full	Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
title_fullStr	Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
title_full_unstemmed	Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients
title_sort	clinical utility of urinary soluble cd163 in evaluation of lupus nephritis patients
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/1d3562f5393f4a25b3eca27a016c9314
work_keys_str_mv	AT nadamgamal clinicalutilityofurinarysolublecd163inevaluationoflupusnephritispatients AT emanrbadawy clinicalutilityofurinarysolublecd163inevaluationoflupusnephritispatients AT esraaatalaat clinicalutilityofurinarysolublecd163inevaluationoflupusnephritispatients AT hamdymibrahim clinicalutilityofurinarysolublecd163inevaluationoflupusnephritispatients AT monahabdelsamea clinicalutilityofurinarysolublecd163inevaluationoflupusnephritispatients
_version_	1718431276358172672

Clinical utility of urinary soluble CD163 in evaluation of lupus nephritis patients

Ejemplares similares